FORT MYERS, Fla., March 19, 2019 /PRNewswire/ — According to research recently published in the New England Journal of Medicine, a novel oral hormonal antagonist, Darolutamide, has been shown as an effective treatment for advanced prostate cancer patients, successfully achieving the phase III trial’s primary endpoint, metastasis-free survival (MFS), a composite endpoint of radiographic progression and overall survival.
The research, conducted by Dr. Neal D. Shore of Carolina Urologic Research Center and Atlantic Urology Clinics, a member of America’s largest integrated cancer care provider 21st Century Oncology, adds to prior early phase trials performed with Darolutamide, further demonstrating both its efficacy and tolerability for advanced prostate cancer patients.
To evaluate the effectiveness of the drug, Dr. Shore, was part of a prospective, randomized, double-blinded global trial evaluating 1,509 male patients with nonmetastatic castration resistant prostate cancer, specifically requiring a prostate-specific antigen doubling time of 10 months or less. Among the men studied, MFS was significantly longer with the use of Darolutamide than with the placebo.
“The positive results learned from the trial will assuredly incorporate Darolutamide as an important treatment option for advanced prostate cancer patients,” said Dr. Shore, an expert in systemic therapies for patients with advanced urologic cancers. “The study will provide clinicians with an additional therapeutic option for castration-resistant prostate cancer patients, especially when reviewing the drug’s well-tolerated safety profile.”
In addition, Dr. Shore serves as the National Urology Research Director for 21st Century Oncology and is involved in numerous trials evaluating new therapeutic pathways and potential targets in genitourinary (GU) oncology.
Dr. Shore published this research in conjunction with Karim Fizazi, MD; Teuvo L. Tammela, MD, PhD; Albertas Ulys, MD; Egils Vjaters, MD; Sergey Polyakov, MD; Mindaugas Jievaltas, MD; Murilo Luz, MD; Boris Alekseev, MD; Iris Kuss, MD; Christian Kappeler, PhD; Amier Snapir, MD, PhD; Toni Sarapohja, M.Sc; and Matthew R. Smith, MD, PhD for the ARAMIS Investigators.
About Atlantic Urology Clinics:
The Atlantic Urology Clinics, LLC (AUC) team is comprised of 13 board certified urologists and 10 physician extenders dedicated to providing cutting edge urologic care. Educated and trained at some of the most prestigious medical schools and teaching hospitals in the nation, the urologists at Atlantic Urology Clinics combine proficiency with exceptional skills in advanced surgical techniques. AUC’s leading edge care and state-of-the-art technology includes on-site radiology, laboratory and pathology services, two ambulatory surgical centers, and a clinical research branch, Carolina Urologic Research Center. AUC offers 10 Urologic Centers of Excellence to conveniently serve patients in and around Horry, Georgetown, Brunswick, and Marion counties.
About 21st Century Oncology:
21st Century Oncology is the nation’s largest integrated cancer care provider. Operating as one dream team in the crusade against cancer, the company carries out its mission with the mindset of fighting for patients like an army and caring for them like a family. 21st Century Oncology employs or is affiliated with more than 940 physicians globally to deliver the most advanced, integrated and compassionate cancer care in personal and convenient settings. Headquartered in Fort Myers, FL, 21st Century Oncology operates 165 treatment centers, including 130 centers located in 15 U.S. states. In addition, the company operates 35 centers located in eight countries in Latin America. For more information, please visit https://www.21co.com.
Media Contact: Samantha Scott, APR
firstname.lastname@example.org | (239) 221-2858
SOURCE 21st Century Oncology